An outstanding achievement for Citryll, one of their notable papers, which had been published some time ago in a reputable journal, secured an impressive third position among the Carbon Mitigation Initiative (CMI) Best Paper Award. This remarkable recognition highlights the significant impact of their research in the scientific community.
Delve deeper into the details of this influential article that discusses the inhibition of NET formation through therapeutic ACPA. The insights shared in this paper contribute to our understanding of cutting-edge advancements in the field and emphasize Citryll’s dedication to pushing the boundaries of knowledge and innovation. Find the article about the CMI Best Paper Award via this link.
More about Citryll
Citryll is taking a new approach to treat autoimmune and other human diseases, such as lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. This approach involves targeting and inhibiting the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules, rather than broadly targeting inflammation or acquired immunity. The latter are the MoAs of current medicines like anti-TNF antibodies, small molecule Jak inhibitors and antagonists of B cell biology like anti-CD20 antibodies. Citryll’s lead programme targets the formation of neutrophil extracellular traps, called NETs and its pathological consequences. Citryll BV is a private pharmaceutical company that is dedicated to the development and commercialisation of therapeutics that target NETosis and NETs. Citryll was founded by ModiQuest B.V., originator of the tACPA patents, Helmuth van Es, CEO Citryll (co-founder of Audion Therapeutics, Galapagos, Antabio and Effecta Pharma), and Renato Chirivi, CSO Citryll and co-inventor of tACPA antibodies.